Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Gain Therapeutics (GANX) Net Margin (2020 - 2023)

Gain Therapeutics (GANX) has 4 years of Net Margin data on record, last reported at 9310.11% in Q1 2023.

  • For Q1 2023, Net Margin fell 203854.0% year-over-year to 9310.11%; the TTM value through Dec 2023 reached 40878.89%, down 4070114.0%, while the annual FY2023 figure was 40878.89%, 4069113.0% down from the prior year.
  • Net Margin reached 9310.11% in Q1 2023 per GANX's latest filing, down from 5347.33% in the prior quarter.
  • Across five years, Net Margin topped out at 36087.19% in Q4 2021 and bottomed at 46506.87% in Q1 2021.
  • Average Net Margin over 4 years is 7381.98%, with a median of 8524.66% recorded in 2020.
  • Peak YoY movement for Net Margin: plummeted -3775117bps in 2021, then surged 3923530bps in 2022.
  • A 4-year view of Net Margin shows it stood at 14149.12% in 2020, then surged by 155bps to 36087.19% in 2021, then crashed by -115bps to 5347.33% in 2022, then plummeted by -74bps to 9310.11% in 2023.
  • Per Business Quant database, its latest 3 readings for Net Margin were 9310.11% in Q1 2023, 5347.33% in Q2 2022, and 7271.57% in Q1 2022.